|
|
|
|
|
|
|
16.11.26 - 20:01
|
Nvidia Bull: AI Growth Story Remains Intact (Bloomberg)
|
|
|
I/O Fund CEO and lead tech analyst Beth Kindig says her long-term Nvidia bull case remains intact despite Jensen Huang's departure, arguing the company could still reach a $20 trillion market value by 2030. She discusses why surging AI compute demand, Nvidia's potential expansion into recurring software revenue and its lowest valuation multiple in years could support the stock - while AMD emerges as a more formidable competitor in rack-scale AI systems. She joins Ed Ludlow on "Bloomberg Tech." (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.11.26 - 14:18
|
Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired (Business Wire)
|
|
|
Lead program OLN324 is a next-generation, Phase 3 investigational, VEGF/Ang2 bispecific antibody being developed for diabetic macular edema and wet age-related macular degenerationAUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (“Ollin”), a privately-held clinical-stage biopharmaceutical company developing therapies for serious eye diseases, today announced it has entered into a definitive agreement to be acquired by Johnson & Johnson for $2.2 billion upfront with the potential for up to approximately $1.1 billion in additional regulatory and commercial milestone payments.
Ollin was founded in 2023 with a mission to identify and accelerate the development of next-generation therapies in ophthalmology. Ollin's lead program is OLN324, a Phase 3 investigational bispecific antibody designed to target VEGF and Ang2 with optimized molecular size and potency. OLN324 is being developed for wet AMD and diabetic macular edema, two serious retinal diseases affecting more than 40 million people worldwide...
|
|